Skandinaviska Enskilda Banken AB publ Has $43.68 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Skandinaviska Enskilda Banken AB publ increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 30.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 472,895 shares of the medical research company’s stock after purchasing an additional 111,605 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.08% of Edwards Lifesciences worth $43,681,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. DSM Capital Partners LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth about $28,000. Crewe Advisors LLC bought a new stake in Edwards Lifesciences during the 1st quarter worth about $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $29,000. Riverview Trust Co bought a new stake in Edwards Lifesciences during the 1st quarter worth about $34,000. Finally, Pingora Partners LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth about $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on EW. Piper Sandler cut their price target on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. The Goldman Sachs Group dropped their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Robert W. Baird cut shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $102.00 to $70.00 in a report on Thursday, July 25th. Finally, Citigroup upped their target price on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Sixteen investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.82.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $67.26 on Friday. The company’s 50 day moving average price is $70.37 and its two-hundred day moving average price is $83.00. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market cap of $40.53 billion, a PE ratio of 28.99, a PEG ratio of 2.85 and a beta of 1.13. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $0.66 EPS. Equities research analysts predict that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,250 shares of company stock worth $1,218,138. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.